Saatci, Ozge http://orcid.org/0000-0002-0124-044X
Cetin, Metin
Uner, Meral http://orcid.org/0000-0001-9927-1246
Tokat, Unal Metin http://orcid.org/0000-0003-0026-368X
Chatzistamou, Ioulia http://orcid.org/0000-0002-6632-8469
Ersan, Pelin Gulizar http://orcid.org/0000-0003-3637-4090
Montaudon, Elodie
Akyol, Aytekin
Aksoy, Sercan http://orcid.org/0000-0003-4984-1049
Uner, Aysegul
Marangoni, Elisabetta http://orcid.org/0000-0002-3337-6448
Sajish, Mathew http://orcid.org/0000-0001-6715-5953
Sahin, Ozgur http://orcid.org/0000-0002-8033-7089
Article History
Received: 28 February 2023
Accepted: 26 September 2023
First Online: 2 November 2023
Competing interests
: O. Sahin is the co-founder and manager of OncoCube Therapeutics LLC, developing TACC3 inhibitors, and the founder and president of LoxiGen, Inc, developing lysyl oxidase inhibitors. The other authors declare no potential conflicts of interest.